Vitamin D deficiency in HIV: A shadow on long-term management?

AIDS Reviews

Volumn 16, Issue 2, 2014, Pages 59-74

  Orkin, Chloe ^a   Wohl, David A ^b   Williams, Andrew ^a   Deckx, Henri ^c  

^a BARTS HEALTH NHS TRUST   (United Kingdom)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

Antiretroviral therapy; HIV; Vitamin D; Vitamin D deficiency

Indexed keywords

ABACAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LAMIVUDINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RILPIVIRINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; VITAMIN D; ZIDOVUDINE; ANTIVIRUS AGENT; BENZOXAZINE DERIVATIVE; VITAMIN;

ARTICLE; DISEASE COURSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; OSTEOMALACIA; OSTEOPENIA; OSTEOPOROSIS; PRACTICE GUIDELINE; PREVALENCE; RICKETS; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN INTAKE; VITAMIN SUPPLEMENTATION; COMPLICATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; IMMUNOLOGY; METABOLISM; RISK FACTOR;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; BENZOXAZINES; DISEASE PROGRESSION; HIV INFECTIONS; HUMANS; OSTEOMALACIA; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; VITAMIN D; VITAMIN D DEFICIENCY; VITAMINS;

EID: 84903776310     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (166)

1. Tsiaras W, Weinstock M. Factors influencing vitamin D status. Acta Derm Venereol. 2011;91:115-24.
2. Adams J, Clemens T, Parrish J, Holick M. Vitamin-D synthesis and metabolism after ultraviolet irradiation of normal and vitamin-D-deficient subjects. N Engl J Med. 1982;306:722-5. (Pubitemid 12183624)
3. Jones G. Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr. 2008;88:582-6S.
4. Levine B, Singer F, Bryce G, Mallon J, Miller O, Coburn J. Pharmacokinetics and biologic effects of calcitrol in normal humans. J Lab Clin Med. 1985;105:239-46. (Pubitemid 15036944)
5. Christakos S, Ajibade D, Dhawan P, Fechner A, Mady L. Vitamin D: metabolism. Endocrinol Metab Clin North Am. 2010;39:243-53.
6. Holick M. Vitamin D deficiency. N Engl J Med. 2007;357:266-81.
7. National Institutes of Health (NIH), Office of Dietary Supplements. Dietary supplement fact sheet: vitamin D (24 June 2011; accessed Sept 30, 2013). Available from: http://ods.od.nih.gov/factsheets/VitaminD-Health-Professional/
8. Vieth R. Vitamin D supplementation, 25-hydroxy vitamin D concentrations, and safety. Am J Clin Nutr. 1999;69:842-56. (Pubitemid 29205056)
9. Wilz D, Gray R, Dominguez J, Leman J. Plasma 1,25-(OH)2-vitamin D concentrations and net intestinal calcium, phosphate, and magnesium absorption in humans. Am J Clin Nutr. 1979;32:2052-60. (Pubitemid 10244801)
10. Mee A, Hoyland J, Braidman I, Freemont A, Davies M, Mawer E. Demonstration of vitamin D receptor transcripts in actively resorbing osteoclasts in bone sections. Bone. 1996;18:295-9. (Pubitemid 26149338)
11. Steingrimsdottir L, Gunnarsson O, Indridason O, Franzson L, Sigurdsson G. Relationship between serum parathyroid hormone levels, vitamin D sufficiency, and calcium intake. JAMA. 2005;294:2336-41. (Pubitemid 41607410)
12. Turner A, Anderson P, Morris H. Vitamin D and bone health. Scand J Clin Lab Invest Suppl. 2012;243:65-72.
13. Wang L, Manson J, Song Y, Sesso H. Systematic review: vitamin D and calcium supplementation in prevention of cardiovascular events. Ann Intern Med. 2010;152:315-23.
14. Chua G, Chan Y, Cheng S. Vitamin D status and peripheral artery disease: evidence so far. Vasc Health Risk Manag. 2011;7:671-5.
15. Vaidya A, Forman J. Vitamin D and hypertension: current evidence and future directions. Hypertension. 2010;56:774-9.
16. Kandula P, Dobre M, Schold J, Schreiber M, Mehrotra R, Navaneethan S. Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials. Clin J Am Soc Nephrol. 2011;6:50-62.
17. Straube S, Derry S, Moore R, McQuay H. Vitamin D for the treatment of chronic painful conditions in adults. Cochrane Database Syst Rev. 2010;1:CD007771.
18. McGrath J, Burner T, Féron F, Mackay-Sim A, Eyles D. Developmental vitamin D deficiency and risk of schizophrenia: a 10-year update. Schizophrenia Bull. 2010;36:1073-8.
19. Kriegel M, Manson J, Costenbader K. Does vitamin D affect risk of developing autoimmune disease? A systematic review. Semin Arthritis Rheum. 2011;40:512-31.
20. Thomas G, Scragg R, Jiang C, et al. Hyperglycaemia and vitamin D: a systematic overview. Curr Diabetes Rev. 2012;8:18-31.
21. Zhou G, Stoitzfus J, Swan B. Optimizing vitamin D status to reduce colorectal cancer risk: an evidentiary review. Clin J Oncol Nurs. 2009;13:E3-17.
22. Yaghiyan L, Colditz G, Drake B. Vitamin D and mammographic breast density: a systematic review. Cancer Causes Control. 2012;23:1-13.
23. Yin L, Grandi N, Raum E, Haug U, Arndt V, Brenner H. Meta-analysis: Circulating vitamin D and ovarian cancer risk. Gynecol Oncol. 2011; 121:369-75.
24. Gilbert R, Martin R, Beynon R, et al. Associations of circulating and dietary vitamin D with prostate cancer risk: a systematic review and doseresponse meta-analysis. Cancer Causes Control. 2011;22:319-40.
25. Urrutia R, Thorp J. Vitamin D in pregnancy: current concepts. Curr Opin Obstet Gynecol. 2012;24:57-64.
26. Devaux S, Castela A, Archier E, et al. Topical vitamin D analogues alone or in association with topical steroids for psoriasis: a systematic overview. J Eur Acad Dermatol Venereol. 2012;26(Suppl 3):52-60.
27. Sandhu M, Casale T. The role of vitamin D in asthma. Ann Allergy Asthma Immunol. 2010;105:191-9.
28. Holick M, Blinkley N, Bischoff-Ferrari H, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2011;96:1191-30.
29. Ross A, Taylor C, Yaktine A, Del Valle H. IOM (Institute of Medicine). 2011. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: The National Academies Press (Accessed Sept 30, 2013). Available from: http://www.nap.edu/catalog.php?record-id=13050
30. Munns C, Simm P, Rodda C, et al. Incidence of vitamin D deficiency rickets among Australian children: an Australian Paediatric Surveillance Unit study. Med J Aust. 2012;196:466-8.
31. Priemel M, von Domarus C, Klatte T, et al. Bone mineralization defects and vitamin D deficiency: histomorphometric analysis of liliac crest bone biopsies and circulating 25-hydroxyvitamin D in 675 patients. J Bone Miner Res. 2010;25:305-12.
32. Tahsin-Swafiri S, Blanco-Navarro I, Pérez-Sacristán B, Millán I, Grandao-Lorencio F. The prevalence of vitamin deficiency in clinical practice is assay-dependent. Clin Nutr. 2012;31:1011-14.
33. Forrest K, Stuhldreher W. Prevalence and correlates of vitamin D deficiency in US adults. Nutr Res. 2011;31:48-54.
34. Daly R, Gagnon C, Lu Z, et al. Prevalence of vitamin D deficiency and its determinants in Australian adults aged 25 years and older: a national, population-based study. Clin Endocrinol. 2012;77:26-35.
35. van Schoor N, Lips P. Worldwide vitamin D status. Best Pract Res Clin Endocrinol Metab. 2011;25:671-80.
36. Brown T, McComsey G. Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D. Antivir Ther. 2010;15:425-9.
37. Choi A, Lo J, Mulligan K, et al. Association of vitamin D insufficiency with carotid intima-media thickness in HIV-infected persons. Clin Infect Dis. 2011;52:941-4.
38. Crutchley R, Gathe J, Mayberry C, Trieu A, Abughosh S, Garey K. Risk factors for vitamin D deficiency in HIV-infected patients in the south central United States. AIDS Res Hum Retroviruses. 2012;28:454-9.
39. Frontini M, Nnadi J, Bairu S, Khan T, Chotalia J, Clark R. Risk factors for suboptimal vitamin D levels among adults with HIV attending an inner-city clinic of New Orleans, Louisiana. J La State Med Soc. 2012; 164:10-12.
40. Havens P, Stephensen C, Hazra R, et al. Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-controlled trial. Clin Infect Dis. 2012;54:1013-25.
41. Kim J, Gandhi V, Psevdos G, Espinoza F, Park J, Sharp V. Evaluation of vitamin D levels among HIV-infected patients in New York City. AIDS Res Hum Retroviruses. 2012;28:235-41.
42. Kwan C, Eckhardt B, Baghdadi J, Aberg J. Hyperparathyroidism and complications associated with vitamin D deficiency in HIV-infected adults in New York City, New York. AIDS Res Hum Retroviruses. 2012;28:1025-32.
43. Lai H, Gerstenblith G, Fishman E, et al. Vitamin D deficiency is associated with silent coronary artery disease in cardiovascularly asymptomatic African Americans with HIV infection. Clin Infect Dis. 2012;54: 1747-55.
44. Rodríguez M, Daniels B, Gunawardene S, Robbins G. High frequency of vitamin D deficiency in ambulatory HIV-positive patients. AIDS Res Hum Retroviruses. 2009;25:9-14.
45. Dao C, Patel P, Overton E, et al. Low vitamin D among HIV-infected adults: prevalence of and risk factors for low vitamin D Levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population. Clin Infect Dis. 2011;52:396-405.
46. French A, Adeyemi O, Agniel D, et al. The association of HIV status with bacterial vaginosis and vitamin D in the United States. J Womens Health. 2011:20;1497-503.
47. Chien C, Carlotti C, Bhatti L, et al. High prevalence of vitamin D deficiency among HIV-infected patients. 18th IAC 2010. [Abstract WEPDB102].
48. Ahmed S, Zinkiewicz P, Ninivaggi M, et al. Prevalence of vitamin D deficiency in HIV populations: an analysis of NHANES. 18th IAC 2010. [Abstract THPE0217].
49. Durand M, Morin H, Daoust C, Couturier M, Tremblay C. Prevalence and determinants of reduced bone mineral density and treatment for osteoporosis in HIV-infected patients in Montréal. 6th IAS Conference 2011. [Abstract CDB053].
50. Bearden A, Abad C, Gangnon R, Sosman J, Binkley N, Safdar N. Crosssectional study of vitamin D levels, immunologic and virologic outcomes in HIV-infected adults. J Clin Endocrinol Metab. 2013;98:1726-33.
51. Gangcuangco L, Chow D, Liang C-Y, et al. Predictors of 25-hydroxyvitamin D levels in HIV-infected patients in Hawaii. Hawaii J Med Pub Health. 2013;72:197-201.
52. Lai S, Fishman E, Gerstenblith G, et al. Vitamin D deficiency is associated with coronary artery calcification in cardiovascularly asymptomatic African Americans with HIV infection. Vasc Health Risk Manag. 2013;9:493-500.
53. Eckard A, Leong T, Avery A, et al. Short communication: high prevalence of vitamin D deficiency in HIV-infected and HIV-uninfected pregnant women. AIDS Res Hum Retroviruses. 2013;29:1224-8.
54. Allavena C, Delpierre C, Cuzin L, et al. High frequency of vitamin D deficiency in HIV-infected patients: effects of HIV-related factors and antiretroviral drugs. J Antimicrob Chemother. 2012;67:2222-30.
55. Conesa-Botella A, Florence E, Lynen L, Colebunders R, Menten J, Moreno-Reyes R. Decrease of vitamin D concentration in patients with HIV infection on a non nucleoside reverse transcriptase inhibitor-containing regimen. AIDS Res Ther. 2010;7:40.
56. Curtis J, Smith B, Weaver M, et al. Ethnic variations in the prevalence of metabolic bone disease among HIV-positive patients with lipodystrophy. AIDS Res Hum Retroviruses. 2006;22:125-31. (Pubitemid 43277147)
57. Focà E, Motta D, Borderi M, et al. Prospective evaluation of bone markers, parathormone and 1,25-(OH)vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz. BMC Infect Dis. 2012;12:38.
58. Fox J, Peters B, Prakash M, Arribas J, Hill A, Moecklinghoff C. Improvement in vitamin D deficiency following antiretroviral regime change: Results from the MONET trial. AIDS Res Hum Retroviruses. 2011;27:29-34.
59. Foissac F, Tréluyer J, Souberbielle J, Rostane H, Urien S, Viard J. Vitamin D3 supplementation scheme in HIV-infected patients based upon pharmacokinetic modeling of 25-hydroxycholecaciferol. Br J Clin Pharmacol. 2013;75:1312-20.
60. Labarga P, Barreiro P, Martín-Carbonero L, et al. Prevalence and mechanisms of hyperparathyroidism in HIV+ patients treated with TDF. 18th CROI 2011. [Abstract 824].
61. Legeai C, Vigouroux C, Souberbielle J, et al. Associations between 25-hydroxyvitamin D and immunologic, metabolic, inflammatory markers in treatment-naive HIV-infected persons: the ANRS CO09 COPANA cohort study. PLoS One. 2013;18:e74868.
62. Mueller N, Fux C, Ledergerber B, et al. High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients. AIDS. 2010;24:1127-34.
63. Pocaterra D, Carenzi L, Ricci E, et al. Secondary hyperparathyroidism in HIV patients: is there any responsibility of highly active antiretroviral therapy? AIDS. 2011;25:1430-3.
64. Pacanowski J, Valin N, Guechot J, et al. Effects of vitamin D3 supplementation on 25-OH vitamin D and PTH concentrations in 483 HIV+ patients. 19th CROI 2012. [Abstract 887].
65. Rosenvinge M, Gedela K, Copas A, et al. Tenofovir-linked hyperparathyroidism is independently associated with the presence of vitamin D deficiency. J Acquir Immune Defic Syndr. 2010;54:496-9.
66. Seminari E, Castagna A, Soldarini A, et al. Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients. HIV Med. 2005;6:145-50. (Pubitemid 40740329)
67. Van Den Bout-Van Den Beukel C, Fievez L, Michels M, et al. Vitamin D deficiency among HIV type 1-infected individuals in the Netherlands: effects of antiretroviral therapy. AIDS Res Hum Retroviruses. 2008;24:1375-82.
68. Vescini F, Cozzi-Lepri A, Borderi M, et al. Prevalence of hypovitaminosis D and factors associated with vitamin D deficiency and morbidity among HIV-infected patients enrolled in a large Italian cohort. J Acquir Immune Defic Syndr. 2011;58:163-72.
69. Viard J, Souberbielle J, Kirk O, et al. Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study. AIDS. 2011;25:1305-15.
70. Welz T, Childs K, Ibrahim F, et al. Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase. AIDS. 2010;24:1923-8.
71. Cervero M, Agud J, García-Lacalle C, et al. Prevalence of vitamin D deficiency and its related risk factor in a Spanish cohort of adult HIV-infected patients: effects of antiretroviral therapy. AIDS Res Hum Retroviruses. 2012;28:963-71.
72. Rachid T, Devitt E, Meyron I, et al. No association of vitamin D levels with individual antiretroviral agents, duration of HIV-infection, alkaline phosphatase levels nor bone mineral density findings. 18th IAC 2010. [Abstract WEPDB105).
73. del Palacio Tamarit M, Pérez-Elías M, Moreno A, Dronda F, Moreno S, Casado J. Hypovitaminosis D and secondary hyperparathyroidism in HIV-positive patients: influence of seasonal variations in Spain. 19th IAC 2012. [Abstract MOPE084].
74. Nunnari G, Pinzone M, Coco C, et al. Low vitamin D in a cohort of HIV-positive patients in eastern Sicily: risk factors for hypovitaminosis D and association with markers of immune activation. 19th IAC 2012. [Abstract MOPE083].
75. Ansemant T, Mahy S, Piroth C, et al. Severe hypovitaminosis D correlates with increased inflammatory markers in HIV infected patients. BMC Infect Dis. 2013;13:7.
76. Bañon S, Perez-Elías M, Moreno A, Dronda F, Moreno S, Casado J. Seasonal variation in 25-hydroxyvitamin D concentrations, secondary hyperparathyroidism and lower bone mineral density in HIV-infected patients. 7th IAS Conference 2013. [Abstract PUB010].
77. Cervero M, Agud J, Torres R, et al. Higher vitamin D levels in HIV-infected out-patients on treatment with boosted protease inhibitor monotherapy. HIV Med. 2013;14:556-62.
78. Pinzone M, Di Rosa M, Celesia B, et al. LPS and HIV gp120 modulate monocyte/macrophage CYP27B1 and CYP24A1 expression leading to vitamin D consumption and hypovitaminosis D in HIV-infected individuals. Eur Rev Med Pharmacol Sci. 2013;17:1938-50.
79. Theodorou M, Sersté T, Van Gossum M, Dewit S. Factors associated with vitamin D deficiency in a population of 2044 HIV-infected patients. Clin Nutr. 2013;http://dx.doi.org/10.1016/j.clnu.2013.04.018.
80. Ramautarsing R, Avihingsanon A, Praditpornsilpa K, et al. Prevalence and risk factors for hypovitaminosis D among HIV+ adults living in the tropics. 19th CROI 2012. [Abstract 882].
81. Wiboonchutikul S, Sungkanuparph S, Kiertiburanakul S, et al. Vitamin D insufficiency and deficiency among HIV-1-infected patients in a tropical setting. J Int Assoc Physicians AIDS Care. 2012;11:305-10.
82. Sudfeld C, Wang M, Aboud S, Giovannucci E, Mugusi F, Fawzi W. Vitamin D and HIV progression among Tanzanian adults initiating antiretroviral therapy. PLoS One. 2012;7:e40036.
83. Etminani-Esfahani M, Khalili H, Jafari S, Abdollahi A, Dashti-Khavidaki S. Effects of vitamin D supplementation on the bone specific biomarkers in HIV infected individuals under treatment with efavirenz. BMC Res Notes. 2012;5:204.
84. Etminani-Esfahani M, Khalili H, Soleimani N, et al. Serum vitamin D concentration and potential risk factors for its deficiency in HIV positive individuals. Curr HIV Res. 2012;10:165-70.
85. Martineau A, Nhamoyebonde S, Oni T, et al. Reciprocal seasonal variation in vitamin D status and tuberculosis notifications in Cape Town, South Africa. Proc Natl Acad Sci USA. 2011;108:19013-17.
86. Hamill M, Ward K, Pettifor J, Norris S, Prentice A. Bone mass, body composition and vitamin D status of ARV-naive, urban, black South African women with HIV infection, stratified by CD4 count. Osteoporos Int. 2013;24;2855-61.
87. Conesa-Botella A, Goovaerts O, Massinga-Loembé M, et al. Low prevalence of vitamin D deficiency in Ugandan HIV-infected patients with and without tuberculosis. Int J Tuberc Lung Dis. 2012;16:1517-21.
88. Bajaj S, Misra V, Bharghav A, Gupta S, Sonkar K, Ibandalin. Association of vitamin D levels, lipid profile and intima media thickness in HIV positive patients. Indian J Endocrinol Metab. 2012;16(Suppl 2):S411-2.
89. Poudel-Tandukar K, Poudel K, Jimba M, Kobayashi J, Johnson C, Palmer P. Serum 25-hydoxyvitamin D levels and C-reactive protein in persons with human immunodeficiency virus infection. AIDS Res Hum Retroviruses. 2013;29:528-34.
90. Havers F, Smeaton L, Detrick B, et al. Vitamin D insufficiency is independently associated with HIV disease progression and death after cART initiation in resource-limited settings. 19th CROI 2012. [Abstract 886].
91. Wohl D, Orkin C, Doroana M, et al. Change in vitamin D levels and risk of severe vitamin D deficiency over 48 weeks among HIV-1-infected, treatment-naive adults receiving rilpivirine or efavirenz in a phase III trial (ECHO). Antivir Ther. [Accepted for publication].
92. Aziz M, Adeyemi O, Agniel D, Weber K, French A, Cohen M. Vitamin D deficiency in Chicago women: when sunlight is not enough. 18th CROI 2011. [Abstract 822].
93. Aziz M, Livak B, Burke-Miller J, et al. Vitamin D insufficiency may impair CD4 recovery among Women's Interagency HIV Study participants with advanced disease on HAART. AIDS. 2013;27:573-8.
94. Adeyemi O, Agniel D, French A, et al. Vitamin D deficiency in HIV-infected and HIV-uninfected women in the United States. J Acquir Immune Def Syndr. 2011;57:197-204.
95. Sroussi H, Burke-Miller J, French A, et al. Association among vitamin D, oral candidiasis, and calprotectinemia in HIV. J Dent Res. 2012;91:666-70.
96. Stein E, Yin M, McMahon D, et al. Vitamin D deficiency in HIV-infected postmenopausal Hispanic and African-American women. Osteoporos Int. 2011;22:477-87.
97. Adeyemi O, Livak B, Orsi J, et al. Vitamin D and insulin resistance in non-diabetic Women's Interagency HIV Study Participants. AIDS Patient Care STDS. 2013;27:320-5.
98. Ross A, Leong T, Avery A, et al. High prevalence of vitamin D deficiency in HIV-infected pregnant women. 6th IAS Conference 2011. [Abstract CDB480].
99. Conrado T, Miranda-Filho Dde B, Ximenes R, et al. Vitamin D deficiency in HIV-infected women on antiretroviral therapy living in the tropics. J Int Assoc Physicians AIDS Care. 2011;10:239-45.
100. Shahar E, Segal E, Rozen G, et al. Vitamin D status in young HIV infected women of various ethnic origins: incidence of vitamin D deficiency and possible impact on bone density. Clin Nutr. 2013;32:83-7.
101. Finkelstein J, Mehta S, Duggan C, et al. Maternal vitamin D status and child morbidity, anemia, and growth in human immunodeficiency virusexposed children in Tanzania. Pediatr Infect Dis J. 2012;31:171-5.
102. Mehta S, Spiegelman D, Aboud S, et al. Lipid-soluble vitamins A, D, and E in HIV-infected pregnant women in Tanzania. Eur J Clin Nutr. 2010;64:808-17.
103. Mave V, Shere D, Gupte N, et al. Vitamin D deficiency is common among HIV-infected breastfeeding mothers in Pune, India, but is not associated with mother-to-child transmission of HIV. HIV Clin Trials. 2012;13:278-83.
104. Bang U, Shakar S, Hitz M, et al. Deficiency of 25-hydroxyvitamin D in male HIV-positive patients: a descriptive cross-sectional study. Scand J Infect Dis. 2010;42:306-10.
105. Chu E, Breaux K, Marcelli M, Rodriguez-Barradas M. Bone disease risk factors and DXA screening in HIV infection: a retrospective study. 19th CROI 2012. [Abstract 876].
106. Tomazic J, Ul K, Volcansek G, et al. Prevalence and risk factors for osteopenia/osteoporosis in an HIV-infected male population. Wien Klin Wochenschr. 2007;119:639-46. (Pubitemid 350239502)
107. Wasserman P, Rubin D. Highly prevalent vitamin D deficiency and insufficiency in an urban cohort of HIV-infected men under care. AIDS Patient Care STDS. 2010;24:223-7.
108. García Aparicio A, Muñoz Fernández A, González J, et al. Abnormalities in the bone mineral metabolism in HIV-infected patients. Clin Rheumatol. 2006;25:537-9.
109. Paul T, Asha H, Thomas N, et al. Hypovitaminosis D and bone mineral density in human immunodeficiency virus-infected men from India, with or without antiretroviral therapy. Endocr Pract. 2010;16:547-53.
110. Hileman C, Labbato D, Storer N, McComsey G. BMD, vitamin D levels and inflammation markers in ARV-naive HIV+ and HIV- adults. 19th CROI 2012. [Abstract 880].
111. Madeddu G, Spanu A, Solinas P, et al. Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy. Q J Nucl Med Mol Imaging. 2004;48:39-48. (Pubitemid 39069663)
112. Milazzo L, Mazzali C, Bestetti G, et al. Liver-related factors associated with low vitamin D levels in HIV and HIV/HCV coinfected patients and comparison to general population. Curr HIV Res. 2011;9:186-93.
113. Nansera D, Graziano F, Friedman D, Bobbs M, Jones A, Hansen K. Vitamin D and calcium levels in Ugandan adults with human immunodeficiency virus and tuberculosis. Int J Tuberc Lung Dis. 2011;15:1522-7.
114. Ormesher B, Dhaliwal S, Nylen E, et al. Vitamin D deficiency is less common among HIV-infected African-American men than in a matched cohort. AIDS. 2011;25:1237-9.
115. Yin M, Lu D, Cremers S, et al. Short-term bone loss in HIV-infected premenopausal women. J Acquir Immune Defic Syndr. 2010;53:202-8.
116. Ross A, Judd S, Kumari M, et al. Vitamin D is linked to carotid intimamedia thickness and immune reconstitution in HIV-positive individuals. Antivir Ther. 2011;16:555-63.
117. Teichmann J, Stephan E, Lange U, et al. Osteopenia in HIV-infected women prior to highly active antiretroviral therapy. J Infect. 2003;46:221-7. (Pubitemid 36758180)
118. Zhang L, Su Y, Hsieh E, et al. Bone turnover and bone mineral density in HIV-1 infected Chinese taking highly active antiretroviral therapy - a prospective observational study. BMC Musculosk Dis. 2013;14:224.
119. Childs K, Fishman S, Constable C, et al. Short communication: Inadequate vitamin D exacerbates parathyroid hormone elevations in tenofovir users. AIDS Res Hum Retroviruses. 2010;26:855-9.
120. Masiá M, Padilla S, Robledano C, López N, Ramos J, Gutiérrez F. Early changes in parathyroid hormone concentrations in HIV-infected patients initiating antiretroviral therapy with tenofovir. AIDS Res Hum Retroviruses. 2012;28:242-6.
121. Bech A, Van Bentum P, Telting D, Gisolf J, Richter C, De Boer H. Treatment of calcium and vitamin D deficiency in HIV-positive men on tenofovir-containing antiretroviral therapy. HIV Clin Trials. 2012;13:350-6.
122. Bonnet E, Ruidavets J-B, Genoux A, et al. Early loss of bone mineral density is correlated with a gain of fat mass in patients starting a protease inhibitor containing regimen: the prospective Lipotrip study. BMC Infect Dis. 2013;13:293.
123. Klassen K, Martineau A, Wilkinson R, Cooke G, Courtney A, Hickson M. The effect of tenofovir on vitamin D metabolism in HIV-infected adults is dependent on sex and ethnicity. PLoS One. 2012;7:e44845.
124. Teichmann J, Lange U, Discher T, Lohmeyer J, Stracke H, Bretzel R. Growth hormone and bone mineral density in HIV-1-infected male subjects. Eur J Med Res. 2008;13:173-8. (Pubitemid 351696264)
125. Sherwood J, Mesner O, Weintrob A, et al. Vitamin D deficiency and its association with low mineral density, HIV-related factors, hospitalization, and death in a predominantly black HIV-infected cohort. Clin Infect Dis. 2012;55:1727-36.
126. Wang C-C, Gopalakrishnan G, Kojic E, Cu-Uvin S. High prevalence of bone demineralization in a cohort of HIV-infected postmenopausal women. 18th IAC 2010. [Abstract WEPE0040].
127. Ramayo E, González-Moreno M, Macías J, et al. Relationship between osteopenia, free testosterone, and vitamin D metabolite levels in HIV-infected patients with and without highly active antiretroviral therapy. AIDS Res Hum Retroviruses. 2005;21:915-21.
128. Yin M, Dobkin J, Brudney K, et al. Bone mass and mineral metabolism in HIV+ postmenopausal women. Osteoporos Int. 2005;16:1345-52. (Pubitemid 41534646)
129. Horizon A, Joseph R, Liao Q, Ross S, Pakes G. Characteristics of foot fractures in HIV-infected patients previously treated with tenofovir versus non-tenofovir-containing highly active antiretroviral therapy. HIV AIDS. 2011;3:53-9.
130. Childs K, Welz T, Samarawickrama A, Post F. Effects of vitamin D deficiency and combination antiretroviral therapy on bone in HIV-positive patients. AIDS. 2012;26:253-62.
131. Fernandez-Fernandez B, Montoya-Ferrer A, Sanz A, et al. Tenofovir nephrotoxicity: 2011 update. AIDS Res Treat. 2011;2011:354908.
132. Lai H, Detrick B, Fishman E, et al. Vitamin D deficiency is associated with the development of subclinical coronary artery disease in African Americans with HIV infection: a preliminary study. J Investig Med. 2012;60:801-7.
133. Longenecker C, Hileman C, Carman T, et al. Vitamin D supplementation and endothelial function in vitamin D deficient HIV-infected patients: a randomized placebo-controlled trial. Antivir Ther. 2012;17:613-21.
134. Shikuma C, Seto T, Liang C-Y, et al. Vitamin D Levels and markers of arterial dysfunction in HIV. AIDS Res Hum Retroviruses. 2012;28:793-7.
135. Huff H, Merchant A, Lonn E, et al. Plasma vitamin D3 concentration not associated with subclinical vascular disease in Canadian HIV-positive adults. 6th IAS Conference 2011. [Abstract TUPE141].
136. Szep Z, Guaraldi G, Shah S, et al. Vitamin D deficiency is associated with type 2 diabetes mellitus in HIV infection. AIDS. 2011;25:525-9.
137. Guaraldi G, Zona S, Orlando G, et al. Vitamin D3 supplementation decreases the risk of diabetes mellitus among patients with HIV infection. 18th CROI 2011. [Abstract 827].
138. Hammond E, McKinnon E, Glendenning P, Williams R, Mallal S, Phillips E. Association between 25-OH vitamin D and insulin is independent of lipoatrophy in HIV. Clin Endocrinol. 2012;76:201-6.
139. Overton E, Grubb J, Baker J, et al. Prevalence and risk factors for insulin resistance in the study to understand the natural history of HIV (SUN study) cohort. 6th IAS Conference 2011. [Abstract TUPE132].
140. Moreno-Pérez O, Portilla J, Escoín C, et al. Impact of vitamin D insufficiency on insulin homeostasis and beta cell function in nondiabetic male HIV-infected patients. HIV Med. 2013;14:540-8.
141. Lake J, Tseng C-H, Hoffman R, Currier J. Associations between 25-hydroxyvitamin D, adipokines, and measures of insulin glucose homeostasis in HIV+ patients. 19th CROI 2012. [Abstract 884].
142. van den Bout-van den Beukel C, van den Bos M, Oyen W, et al. The effect of cholecalciferol supplementation on vitamin D levels and insulin sensitivity is dose related in vitamin D-deficient HIV-1-infected patients. HIV Med. 2008;9:771-9.
143. Finkelstein J, Mehta S, Duggan C, et al. Predictors of anaemia and iron deficiency in HIV-infected pregnant women in Tanzania: a potential role for vitamin D and parasitic infections. Public Health Nutr. 2012;15:928-37.
144. Mehta S, Giovannucci E, Mugusi F, et al. Vitamin D status of HIV-infected women and its association with HIV disease progression, anemia, and mortality. PLoS One. 2010;5:e8770.
145. Merhi Z, Seifer D, Weedon J, et al. Circulating vitamin D correlates with serum antimüllerian hormone levels in late-reproductive-aged women: Women's Interagency HIV Study. Fertil Steril. 2012;98:228-34.
146. Bang U, Kolte L, Hitz M, et al. Correlation of increases in 1,25-dihydroxyvitamin D during vitamin D therapy with activation of CD4+ T lymphocytes in HIV-1-infected males. HIV Clin Trials. 2012;13:162-70.
147. Mehta S, Mugusi F, Spiegelman D, et al. Vitamin D status and its association with morbidity including wasting and opportunistic illnesses in HIV-infected women in Tanzania. AIDS Patient Care STDS. 2011; 25:579-85.
148. Sudfeld C, Giovannucci E, Isanaka S, et al. Vitamin D status and incidence of pulmonary tuberculosis, opportunistic infections, and wasting among HIV-infected Tanzanian adults initiating antiretroviral therapy. J Infect Dis. 2013;207:378-85.
149. Price P, Haddow L, Affandi J, et al. Plasma levels of vitamin D in HIV patients initiating antiretroviral therapy do not predict immune restoration disease associated with mycobacterium tuberculosis. AIDS Res Hum Retroviruses. 2012;28:1216-9.
150. Mehta S, Hunter D, Mugusi F, et al. Perinatal outcomes, including mother-to-child transmission of HIV, and child mortality and their association with maternal vitamin D status in Tanzania. J Infect Dis. 2009; 200:1022-30.
151. Ellfolk M, Norlin M, Gyllensten K, Wikvall K. Regulation of human vitamin D3 25-hydroxylases in dermal fibroblasts and prostate cancer LNCaP cells. Mol Pharmacol. 2009;75:1392-99.
152. Landriscina M, Altamura S, Roca L, et al. Reverse transcriptase inhibitors induce cell differentiation and enhance the immunogenic phenotype in human renal clear-cell carcinoma. Int J Cancer. 2008;122:2842-50. (Pubitemid 351631388)
153. Gupta S, Shen C, Moe S, Kamendulis L, Goldman M, Dubé M. Worsening endothelial function with efavirenz compared to protease inhibitors: a 12-month prospective study. PLoS One. 2012;7:e45716.
154. Cozzolino M, Vidal M, Arcidiacono M, Tebas P, Yarasheski K, Dusso A. HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. AIDS. 2003;17:513-20. (Pubitemid 36293104)
155. Bolland M, Grey A, Horne A, et al. Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial. J Clin Endocrinol Metab. 2007;92:1283-8. (Pubitemid 46556399)
156. Bolland M, Grey A, Horne A, et al. Effects of intravenous zoledronate on bone turnover and BMD persist for at least 24 months. J Bone Miner Res. 2008;23:1304-8. (Pubitemid 352040185)
157. Huang J, Meixner L, Fernandez S, McCutchan J. A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis. AIDS. 2009;23:51-7.
158. Guaraldi G, Orlando G, Madeddu G, et al. Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis. HIV Clin Trials. 2004;5:269-77. (Pubitemid 39545399)
159. McComsey G, Kendall M, Tebas P, et al. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. AIDS. 2007;21:2473-82. (Pubitemid 350145179)
160. Mondy K, Powderly W, Claxton S, et al. Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection. J Acquir Immune Defic Syndr. 2005;38:426-31. (Pubitemid 40381552)
161. Rozenberg S, Lanoy E, Bentata M, et al. Effect of alendronate on HIV-associated osteoporosis: a randomized, double-blind, placebo-controlled, 96-Week trial (ANRS 120). AIDS Res Hum Retroviruses. 2012;28:972-80.
162. EACS guidelines. Version 6.1, November 2012 (Accessed Sept 30, 2013). Available from: http://www.europeanaidsclinicalsociety.org/images/stories/EACS- Pdf/EacsGuidelines-v6.1-2edition.pdf
163. DHHS guidelines. Updated February 2013 (Accessed Sept 30, 2013). Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/ adultandadolescentgl.pdf
164. Thompson A, Aberg J, Hoy J, et al. Antiretroviral treatment of adult HIV infection, 2012 recommendations of the International Antiviral Society- USA Panel. JAMA. 2012;308:387-402.
165. Williams I, Churchill D, Anderson J, et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med. 2012;13(Suppl 2):1-85.
166. Gama R. Vitamin D: some perspectives please. BMJ. 2012;345e;4695.